Ohio State Navbar

Our Team

Meng Welliver, MD, PhD




Assistant Professor, Radiation Oncology







  • 2015: Selected participant, Early Career Women Faculty Professional Development Seminar
  • 2015: American Cancer Society Institutional Grant Award
  • 2014-2015: Selected participant, RSNA Advanced Grant Writing Course
  • 2011: American Brachytherapy Society Travel Award                                            
  • 2010: ASTRO Young Scientist Investigator Award             
  • 2010: Selected participant, AACR/ASCO (Vail) Workshop in Clinical Cancer Research    
  • 2008: Selected participant, RSNA Introduction to Academic Radiology program   
  • 2008: B. Leonard Holman Research Scholar, American Board of Radiology
  • 2002-2004: Alumni Society Endowed Scholarship, Penn State University 
  • 2002: Cancer Research Training Award, National Institutes of Health     
  • 2001: Hammersla Scholarship, Pennsylvania State University,                         
  • 2000: Young Investigator Travel Award, AACR                                                    
  • 1999: Chair's Travel Award, DNA Repair Gordon Conference                           
  • 1998: Dean's Travel Award, Penn State College of Medicine                              
  • 1987-1989: Academic Excellence Award, Beijing Medical University                           


  • 2008-Present: American Society of Clinical Oncology (ASCO)
  • 2007-Present: American Society for Therapeutic Radiology and Oncology (ASTRO)
  • 2007-Present: American Brachytherapy Society
  • 2005-Present: Radiological Society of North America (RSNA)
  • 1998-Present: American Association for Cancer Research (AACR)


  • Xu-Welliver M, Kanugula S, and Pegg AE. Isolation of human O6-alkylguanine­DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Research 58: 1936-1945, 1998.  PMID: 9581836

  • Xu-Welliver M, Leitao J, Kanugula S, and Pegg AE. Alteration of the conserved residue Tyrosine-158 to histidine renders human O6-alkylguanine-DNA alkyltransferase insensitive to the inhibitor O6-benzylguanine. Cancer Research 59: 1514-1519, 1999.  PMID: 10197622

  • Loktionova N, Xu-Welliver M, Crone T, Kanugula S, and Pegg AE. Mutant forms of O6-alkylguanine-DNA alkyltransferase protect CHO cells from killing by BCNU plus O6-benzylguanine or O6-8-Oxo-benzylguanine. Biochemical Pharmacology 58: 237-244, 1999.  PMID: 10423163

  • Xu-Welliver M, Leitao J, Kanugula S, Meehan W, and Pegg AE. The role of codon 160 in sensitivity of human O6-alkylguanine-DNA alkyltransferase to O6-benzylguanine. Biochemical Pharmacology 58: 1279-1285,1999.  PMID: 10487529

  • Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, and Gerson SL. Characterization of the P140K , PVP (138-140) MLK and G156A O6-methylguanine­DNA methyltransferase mutants: implication for drug resistance gene therapy. Human Gene Therapy 10: 2769-2778, 1999.  PMID: 10584923

  • Xu-Welliver M and Pegg AE. Point mutations at multiple sites including highly conserved amino acids maintain activity but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylguanine. Biochemical J. 347 (2): 519-526, 2000.  PMCID: PMC1220985

  • Xu-Welliver M, Kanugula S, Loktionova N, Crone TM, and Pegg AE. Conserved residue lysine-165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine. Biochemical J. 347 (2): 527-534, 2000.  PMCID: PMC1220986

  • Liu H, Xu-Welliver M, and Pegg AE. The role of human O6-alkylguanine-DNA alkyltransferase in promoting 1, 2-dibromoethane-induced genotoxicity in Escherichia coli. Mutation Research 452 (1): 1-10, 2000.  PMID: 10894884

  • Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, Seshadri R, Pegg AE, and Williams DA. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Research 60 (18): 5187-5195, 2000.  PMID: 11016647

  • Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM and Dolan ME. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity in CHO cells expressing wild type and mutant O6-alkylguanine-DNA alkyltransferase. Cancer Research 60 (19): 5464-5469, 2000.  PMID: 11034089

  • Xu-Welliver M and Pegg AE. Degradation of the alkylated form of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 23(5):823-830, 2002.  PMID: 12016156

  • Liu L, Xu-Welliver M and Pegg AE. Inactivation and degradation of O6-alkylguanine-DNA alkyltransferase after reaction with Nitric Oxide. Cancer Research 62 (11): 3037-3043, 2002.  PMID: 12036910

  • Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 112(12):1887-94, 2003.  PMCID: PMC296999

  • Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, Harris CC, Rotter V. The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 25(1):11-19, 2004.  PMID: 14555612

  • Li G, Xie B, Li X, Chen Y, Wang Q, Xu Y, Xu-Welliver M and Zou L. Down-regulation of Survivin and Hypoxia-Inducible Factor 1α by  β-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother Radiopharm. 2012 Feb;27(1):56-64.  PMID: 22248028

  • Shen J, Metz JM, Zhu TC, Panetta J, Finlay JC, Xu-Welliver M, Plastaras JP, Bar Ad V, Both S. Dosimetric consequences of pancreatic tumor motion when predetermined treatment margins are employed during intensity-modulated radiation therapy. Journal of BUON 17: 526-532, 2012.              PMID: 23033294

  • Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A. The Role of Qualitative and Quantitative Analysis of F18-FDG Positron Emission Tomography in Predicting Pathologic Response Following Chemoradiotherapy in Patients with Esophageal Carcinoma. J Gastrointest Cancer EPUB 2012 Jul 10.  PMID: 22777832

  • Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M and Kong M. The B55α subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Molecular Cell 50(2): 200-11, 2013.        PMID: 23499005

  • Lin SH, George TJ, et al, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst. 105(10): 686-93, 2013.  PMID: 23503600

  • Xu-Welliver M and Lin LL. Evaluation of a Balloon-based vaginal packing system and patient controlled analgesia for patients with cervical cancer undergoing high dose rate intracavitary brachytherapy.  Practical Radiation Oncology 3: 263-268, 2013 PMID 24674396

  • Lieber DA, Walston SA, Cavaliere R, et al, Xu-Welliver M, Xia F and Kendra KL. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib, Melanoma Research.  2014 Epub ahead of print. PMCID: PMC4372136

  • Lu LC, Filippi JD, Patel A, Nilendu G, Weldon M, et al, *Welliver, MX. A Clinical dosimetry analysis of total body irradiation for leukemia patients, IJMPCERO, 2014, 3, 31-42,

  • Shilo K, Wu X, Sharma S, Welliver M, Duan W, Villalona-Calero M, Fukuoka J, Sif S, Baiocchi R, Hitchcock CL, Zhao W and Otterson GA. Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors. Diagnostic Pathology. 8: 201, 2013, PMID: 24326178

  • Yi R, Walston S, Welliver MX, Chakravarti A and Quick A. Improving intra-fractional target position accuracy using a 3D surface surrogate for left breast irradiation using the respiratory-gated deep-inspiration breath-hold technique. Plos One 9 (5): e97933, 2014

  • Xu-Welliver M, Yuh WTC, Fielding JR, et al and Mayr NA, Imaging across the Life Span: Innovations in Imaging and Therapy for Gy­necologic Cancer. RadioGraphics 34:1062–1081, 2014, PMCID: PMC4319524

  • Wong P, Houghton P, Kirsch DG, Finkelstein SE, Monjazeb AM, Xu-Welliver M, Dicker AP, Ahmed M, Vikram B, Teicher BA, Coleman CN, Machtay M, Curran WJ, Wang D. Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas. J Natl Cancer Inst. 106 (11), 2014.

  • Majithia L, Rong Y, Siddiqui F, Hattie T, Gupta N, Weldon M, Chakravarti A, Wong HK, Porcu P, Xu-*Welliver M. Treating cutaneous T-cell lymphoma with highly irregular surfaces with photon irradiation using rice as tissue compensator. Front Oncol. 5:49, 2015, PMCID: PMC4338671

  • Li G, Xie B, Li X, Chen Y, Xu Y, Xu-Welliver M, Zou L. Downregulation of peroxiredoxin-1 by β-elemene enhances the radiosensitivity of lung adenocarcinoma xenografts. Oncol Rep. 33(3):1427-33, 2015

  • Rong Y, Evans J, Xu-Welliver M, Pickett C, Jia G, Chen Q, Zuo L Dosimetric evaluation of intensity-modulated radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for hippocampal-avoidance whole brain radiotherapy. PloS One: 10(4): e0126222, 2015, PMCID: PMC4404135.

  • Tyler KH, Haverkos BM, Hastings J, Hu E, Philips R, Gru AA, Welliver MX, Mishra A, Wong HK, Porcu P. The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. Front Oncol. 5:136, 2015. PMCID: PMC4470273

  • Haverkos BM, Tyler KH, Welliver MX, et al  Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of the Ohio State University. The Oncologist, Accepted 2015

  • Miller ED, Xu-Welliver M, Haglund KE. The role of modern radiation therapy in the management of extremity sarcomas. J Surg Oncol 111(5): 599-603, 2015 PMID: 25366825

  • Rong Y, Bazan JG, Sekhon A, Haglund K, Xu-Welliver M, Williams T. Minimal Inter-Fractional Fiducial Migration during Image-Guided Lung Stereotactic Body Radiotherapy Using SuperLock Nitinol Coil Fiducial Markers. PLoS One. 2015 Jul 9;10(7):e0131945. PMCID: PMC4497733